Envista Holdings Corporation — Form 8-K Summary
Business context and reporting period
The Form 8-K, dated January 3, 2022, reports events occurring on December 30–31, 2021. Envista completed the divestiture of its KaVo dental treatment unit and instrument business to Planmeca pursuant to a September 7, 2021 master sale and purchase agreement.
Key financial and transaction metrics
- Cash consideration received at closing: $317.3 million, subject to purchase-price adjustments.
- Expected earnout payment: $30 million in the first quarter of 2022.
- Estimated additional adjustments: $36.2 million, expected in the second quarter of 2022.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet amounts associated with the transaction.
Material changes versus the prior comparable period
The filing describes a strategic divestiture rather than period financial results. Compared with the previously disclosed transaction terms, the December 30 amendment deferred the transfer of assets in Russia, China, and Brazil until Planmeca forms local entities and the applicable asset-transfer agreements are executed and completed. The amendment did not change the preliminary purchase price paid at closing.
Guidance, outlook, risks, contingencies, and unusual items
- The expected $30 million earnout and estimated $36.2 million of adjustments remain subject to the terms and conditions of the purchase agreement.
- Local asset transfers in Russia, China, and Brazil remain deferred and depend on formation of purchaser entities and completion of local closing documentation.
- The filing does not provide management guidance or broader operating outlook commentary.
- The full amendment is to be filed with Envista’s Form 10-K for the year ended December 31, 2021; the filing’s description is qualified by reference to the definitive transaction documents.
Important facts for investors to verify
- Verify the final purchase price, including all closing adjustments, the expected $30 million earnout, and the estimated $36.2 million adjustment.
- Confirm completion dates and terms for the deferred Russia, China, and Brazil asset transfers.
- Review the Form 10-K for the accounting treatment, gain or loss on divestiture, tax effects, and any impact on reported segments and continuing operations.
- Review the filed amendment and purchase agreement for additional conditions, indemnities, contingencies, and settlement mechanics.